Spectrum of Bacille Calmette-Guerin (BCG) Infection after Intravesical BCG Immunotherapy

Gonzalez, Omar Y.; Musher, Daniel M.; Brar, Indira; Furgeson, Seth; Boktour, Maha R.; Septimus, Edward J.; Hamil, Richard J.; Graviss, Edward A.
January 2003
Clinical Infectious Diseases;1/15/2003, Vol. 36 Issue 2, p140
Academic Journal
Intravesical instillation of bacille Calmette-Guérin (BCG) effectively treats transitional cell carcinoma of the bladder. Occasionally, BCG infection complicates such treatment. In some patients, infection appears early (within 3 months after instillation) and is characterized by generalized symptoms, with pneumonitis and hepatitis. Late-presentation disease occurs >1 year after the first BCG treatment and usually involves focal infection of the genitourinary tract (the site at which bacteria were introduced) and/or other sites that are typical for reactivation of mycobacterial disease, such as the vertebral spine or the retroperitoneal tissues. Noncaseating granulomas are found in the majority of cases, whether early or late. Most patients respond to treatment with antituberculous drugs; in early-presentation disease, when features of hypersensitivity predominate, glucocorticosteroids are sometimes added. Late localized infection often requires surgical resection.


Related Articles

  • Gender Does Not Affect BCG Therapy.  // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p41 

    The article reports on the study conducted by Stephen A. Boorjian of Fox Chase Cancer Center in Philadelphia, Pennsylvania, stressing that intravesical bacilli Calmette-Guérin (BCG) therapy does not cure high-risk non-muscle-invasive bladder cancer in men and women.

  • BCG.  // Reactions Weekly;03/23/2013, Issue 1445, p12 

    The article presents a case study of the development of fatal systemic complications in a 63-year-old man while receiving BCG immunotherapy for resected bladder cancer.

  • Bladder Cancer: Current Optimal Intravesical Treatment. Lamm, Donald L.; McGee, William R.; Hale, Kaye // Urologic Nursing;Oct2005, Vol. 25 Issue 5, p323 

    The article presents information about the treatment of bladder cancer by using intravesical bacillus Calmette-Guerin (BCG) immunotherapy. This therapy with a three week maintenance schedule is the best treatment for the high-risk tumors. Side effects of BCG immunotherapy can be decreased by...

  • BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model. Rentsch, Cyrill A.; Biot, Claire; Gsponer, Joël R.; Bachmann, Alexander; Albert, Matthew L.; Breban, Romulus // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Intravesical Bacillus Calmette Guérin (BCG) immunotherapy is considered the standard of care for treatment of non-muscle invasive bladder cancer; however the treatment parameters were established empirically. In order to evaluate potential optimization of clinical parameters of BCG induction...

  • BCG.  // Reactions Weekly;5/27/2006, Issue 1103, p4 

    The article reports the case study of a 72-year-old woman who developed acute granulomatous interstitial nephritis during treatment with intravesical Bacillus Calmette-Guerin (BCG) for bladder cancer and was subsequently treated with oral prednisone.

  • Avoid statins during BCG for bladder cancer?  // Reactions Weekly;1/13/2007, Issue 1134, p5 

    The article discusses research being done on the use of statins during immunotherapy with Bacille Calmette-Guerin (BCG) for bladder cancer. It references a study by P. Hoffmann et al published in the December 21, 2006 issue of the "New England Journal of Medicine." According to the...

  • Previous Bladder Cancer History in Patients with High-Risk, Non-muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History. Mitrakas, Lampros P.; Zachos, Ioannis V.; Tzortzis, Vassileios P.; Gravas, Stavros A.; Rouka, Erasmia C.; Dimitropoulos, Konstantinos I.; Vandoros, Gerasimos P.; Karatzas, Anastasios D.; Melekos, Michael D.; Papavassiliou, Athanasios G. // Cancer Research & Treatment;2015, Vol. 47 Issue 3, p495 

    Purpose: The purpose of this study was to assess the correlation of previous bladder cancer history with the recurrence and progression of patients with high-risk non-muscle-invasive bladder cancer treated with adjuvant Bacillus Calmette-Guérin (BCG) and to evaluate their natural history....

  • Gastrointestinal Crohn-like disease following BCG therapy. Pizzi, Marco; Albertoni, Laura; Stefanizzi, Lavinia; Mescoli, Claudia; Rugge, Massimo // International Journal of Colorectal Disease;Dec2015, Vol. 30 Issue 12, p1745 

    The article presents a case study of a 62-year-old male diagnosed with Crohn-like granoulomatous gastro-enteritis following Bacillus of Calmette Guerin (BCG) therapy for treatment of superficial bladder carcinoma. It mentions that the patient underwent esophago-gastroduodenoscopy (EGDS) and...

  • Unmoderated Posters: Oncology - Bladder.  // Canadian Urological Association Journal;Jun2014 Supplement 3, Vol. 8 Issue 5/6, pS102 

    The article presents abstracts on bladder cancer treatment including the role of contrast media, substance to improve the visibility of internal organs for radiography in upper tract surveillance, efficiency of mitomycin-C hyperthermia and response in patients receiving BCG induction therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics